---
title: "Can-Fite BioPharma (CANF) news: reverse split and offering"
url: "https://aibio.space/companies/can-fite-biopharma/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "CANF reverse split and offering news: Can-Fite details 1-for-3,000 reverse split and ADS ratio change in 6-K. Can-Fite BioPharma Ltd. (TASE: CANF), Israel."
---

CANF Can-Fite BioPharma Ltd. TASE · Israel

# Can-Fite BioPharma (CANF) news CANF reverse split and offering news

Listings · 2026-09-08

## [Can-Fite details 1-for-3,000 reverse split and ADS ratio change in 6-K](https://aibio.space/news/can-fite-details-1-3-000-reverse-split-ads-ratio-change-6/)

A September 2026 report sets out a 1-for-3,000 reverse split of Can-Fite's ordinary shares in January 2026, and a change that cut each ADS from 300 ordinary shares to two. The company also lists the risk of failing NYSE American continued listing standards.

## Latest Can-Fite BioPharma news

1. 2026-08-28 Financings [Can-Fite files $100,000,000 shelf with at-the-market program of up to $1,065,000](https://aibio.space/news/can-fite-files-100-000-000-shelf-market-program-up-1-065-000/) Can-Fite BioPharma's shelf sets a ceiling of $100,000,000, but the at-the-market sales agreement with H.C. Wainwright & Co., LLC covers only $1,065,000, a limit set by its public float.

## Can-Fite BioPharma at a glance

- **Ticker**: CANF

- **Listing**: TASE

- **Country**: Israel

- **Cash, Dec 31, 2025**: $5.5 million

### Related companies

- [SciSparc](https://aibio.space/companies/scisparc/) NASDAQ: SPRC
- [Sol-Gel Technologies](https://aibio.space/companies/sol-gel-technologies/) NASDAQ: SLGL
- [Eocene](https://aibio.space/companies/eocene/) NASDAQ: EOCN
- [NeuroSense Therapeutics](https://aibio.space/companies/neurosense-therapeutics/) NASDAQ: NRSN
- [Redhill Biopharma](https://aibio.space/companies/redhill-biopharma/) NASDAQ: RDHL
- [EPITOMEE MEDICAL LTD](https://aibio.space/companies/epitomee-medical/) TASE: EPIT
- [MediWound](https://aibio.space/companies/mediwound/) NASDAQ: MDWD
- [PRF Technologies](https://aibio.space/companies/prf-technologies/) NASDAQ: PRFX

### Also on TASE

- [BioLineRX](https://aibio.space/companies/biolinerx/) BLRX
- [NEXTAGE Therapeutics](https://aibio.space/companies/nextage-therapeutics/) NXTG
- [Psyrex CNS Bio-Tech](https://aibio.space/companies/psyrex-cns-bio-tech/) PSRX
- [Rekah Pharmaceutical Industry](https://aibio.space/companies/rekah-pharmaceutical-industry/) REKA
- [Teva Pharmaceutical Industries](https://aibio.space/companies/teva-pharmaceutical-industries/) TEVA
- [Rafa Laboratories](https://aibio.space/companies/rafa-laboratories/) RAFA

## Can-Fite BioPharma annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | [$405,000](https://www.sec.gov/Archives/edgar/data/1536196/000121390026034447/) | [$674,000](https://www.sec.gov/Archives/edgar/data/1536196/000121390026034447/) |
| Research and development | [$6.7 million](https://www.sec.gov/Archives/edgar/data/1536196/000121390026034447/) | [$5.8 million](https://www.sec.gov/Archives/edgar/data/1536196/000121390026034447/) |
| Net income (loss) | [-$9.8 million](https://www.sec.gov/Archives/edgar/data/1536196/000121390026034447/) | [-$7.9 million](https://www.sec.gov/Archives/edgar/data/1536196/000121390026034447/) |
| Cash from operations | [-$8.9 million](https://www.sec.gov/Archives/edgar/data/1536196/000121390026034447/) | [-$7.6 million](https://www.sec.gov/Archives/edgar/data/1536196/000121390026034447/) |
| Cash and equivalents | [$5.5 million](https://www.sec.gov/Archives/edgar/data/1536196/000121390026034447/) | [$4.8 million](https://www.sec.gov/Archives/edgar/data/1536196/000121390026034447/) |
| Short-term investments | [$1,000](https://www.sec.gov/Archives/edgar/data/1536196/000121390026034447/) | [$5,000](https://www.sec.gov/Archives/edgar/data/1536196/000121390026034447/) |

Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $5.5 million, plus short-term investments of $1,000, $5.5 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Can-Fite BioPharma

Did Can-Fite BioPharma do a reverse stock split?

Our latest story on this, dated Sep 8, 2026: "Can-Fite details 1-for-3,000 reverse split and ADS ratio change in 6-K". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/can-fite-details-1-3-000-reverse-split-ads-ratio-change-6/).

Has Can-Fite BioPharma raised money recently?

Our latest story on this, dated Aug 28, 2026: "Can-Fite files $100,000,000 shelf with at-the-market program of up to $1,065,000". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/can-fite-files-100-000-000-shelf-market-program-up-1-065-000/).

What is the ticker symbol of Can-Fite BioPharma?

Can-Fite BioPharma Ltd. trades under the ticker CANF on TASE.

Where is Can-Fite BioPharma listed?

Can-Fite BioPharma Ltd. is listed on TASE. Our directory also records these other listings: AMEX:CANF.

What is the SEC CIK of Can-Fite BioPharma?

The SEC Central Index Key (CIK) for Can-Fite BioPharma Ltd. is 1536196. Its filings are on SEC EDGAR.

How many shares does Can-Fite BioPharma have outstanding?

2,618,425 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-26.

Which country or territory is Can-Fite BioPharma listed under?

Our directory records Can-Fite BioPharma Ltd. under Israel.

What does Can-Fite BioPharma do?

Our directory classifies Can-Fite BioPharma Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Can-Fite BioPharma?

The ISIN recorded for Can-Fite BioPharma Ltd. is IL0010944739.

Does aibio.space cover Can-Fite BioPharma?

aibio.space lists Can-Fite BioPharma Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Can-Fite BioPharma incorporated?

SEC records list its state or country of incorporation as L3.

What was Can-Fite BioPharma's revenue last year?

$405,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is Can-Fite BioPharma profitable?

Can-Fite BioPharma Ltd. reported a net loss of $9.8 million for the fiscal year ended Dec 31, 2025, and used $8.9 million of cash in operations, per its annual report to the SEC.

How much does Can-Fite BioPharma spend on research and development?

$6.7 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Can-Fite BioPharma have?

$5.5 million in cash and short-term investments at Dec 31, 2025, per its 20-F.

## Investor discussion: Can-Fite BioPharma

Members talk about Can-Fite BioPharma (CANF). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Can-Fite BioPharma, newest first. Each line links the filing it comes from.

1. 2026-09-08 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1536196/000121390026097856/ea030436701ex99-1.htm)
2. 2026-08-28 Financings Reported a financing. SEC Form F-3. [Source](https://www.sec.gov/Archives/edgar/data/1536196/000121390026095053/ea0303306-f3_canfite.htm)
3. 2025-12-23 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1536196/000121390025125421/ea027054801ex99-1_canfite.htm)
4. 2025-12-16 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1536196/000121390025121959/ea026985501ex99-1_canfite.htm)
5. 2025-10-03 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1536196/000121390025096097/ea025922001ex99-1_canfite.htm)
6. 2025-09-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1536196/000121390025087400/ea025678401ex99-1_canfite.htm)
7. 2025-07-23 Financings Reported a financing. SEC Form F-1. [Source](https://www.sec.gov/Archives/edgar/data/1536196/000121390025067001/ea0249824-f1_canfitebio.htm)
8. 2025-04-14 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1536196/000121390025031598/ea023824701ex99-1_canfite.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open TASE:CANF on TradingView](https://www.tradingview.com/symbols/TASE-CANF/).

## SEC filings and registration

- **SEC name**: Can-Fite BioPharma Ltd.

- **CIK**: 1536196

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: CANF (NYSE)

- **State or country of incorporation**: L3

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer

- **Business address**: 26 BEN GURION STREET, RAMAT GAN, Israel, 5257346

- **Phone**: 972 39241114

- **Shares outstanding**: 2,618,425 as of 2025-12-31 (20-F filed 2026-03-26)

### Recent filings (8-K and 6-K are the company's own announcements)

- [6-K](https://www.sec.gov/Archives/edgar/data/1536196/000121390026098205/ea0304939-6k_canfite.htm) filed 2026-09-09
- [6-K](https://www.sec.gov/Archives/edgar/data/1536196/000121390026097856/ea0304367-6k_canfite.htm) filed 2026-09-08
- [6-K](https://www.sec.gov/Archives/edgar/data/1536196/000121390026097048/ea0304400-6k_canfite.htm) filed 2026-09-03
- [6-K](https://www.sec.gov/Archives/edgar/data/1536196/000121390026096480/ea0304383-6k_canfite.htm) filed 2026-09-02
- [6-K](https://www.sec.gov/Archives/edgar/data/1536196/000121390026096442/ea0304201-6k_canfite.htm) filed 2026-09-02
- [6-K](https://www.sec.gov/Archives/edgar/data/1536196/000121390026090478/ea0302324-6k_canfite.htm) filed 2026-08-17
- [6-K](https://www.sec.gov/Archives/edgar/data/1536196/000121390026088029/ea0301726-6k_canfite.htm) filed 2026-08-12
- [6-K](https://www.sec.gov/Archives/edgar/data/1536196/000121390026084244/ea0300232-6k_canfite.htm) filed 2026-08-03

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001536196), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Can-Fite BioPharma Ltd. is a public biotech or pharmaceutical company listed on TASE under the ticker CANF, recorded under Israel. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Can-Fite BioPharma Ltd.

- **Ticker**: CANF

- **Listing**: TASE

- **Country or territory**: Israel

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: IL0010944739

- **Other listed symbols**: AMEX:CANF

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/TASE-CANF/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/can-fite-biopharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Can-Fite BioPharma (CANF) news: reverse split and offering", 2026-10-31, https://aibio.space/companies/can-fite-biopharma/